...VLP (CoVLP, MT-2766) CpG 1018 Interferon beta (IFNB) (AZD9412, SNG001, sng-1, SGN-1) Johnson & Johnson Inovio Pharmaceuticals Inc. Medicago Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Synairgen...

...syndrome (ARDS). By contrast, Richard Marsden, CEO of Synairgen plc...
...use of steroids and IFNβ. Marsden said Synairgen’s...
...a 101-patient double-blind Phase II trial of Synairgen’s...

...estimates, while Tecentriq atezolizumab was roughly in line.Synairgen...
...with heart failure. Consensus estimates provided by FactSet. BC Staff Astellas AtheroChem Synairgen Boehringer...

...Data suggesting an inhaled IFNB1 product from Synairgen can reduce the chance a patient with COVID-19...
...if and when the cytokine provides a benefit over standard of care or other antivirals. Synairgen...
...duration of mechanical ventilation. Targets IFNB1 - Interferon-β Elizabeth S. Eaton, Staff Writer Interferon beta (IFNB) (AZD9412, SNG001, sng-1, SGN-1) Synairgen...

...which one to bring into the clinic. IMV hasn’t yet determined a clinical development timeline. Synairgen...
...GmbH EUSA Pharma Ltd. CanSino Biologics Inc. Johnson & Johnson BGI Genomics Co. Ltd. U.S. Department of Health and Human Services Synairgen...

...Los Angeles, Calif. email: lily.duyushen@gmail.com CONTACT: Ren Sun, same affiliation as above email: rsun@mednet.ucla.edu Jaime De Leon Interferon beta (IFNB) Interferon University...

...reverses autoimmune diabetes.” Science Translational Medicine (2017) Mark Zipkin, Staff Writer and Karen Tkach Tuzman, Senior Writer Interferon beta (IFNB) Boston...

...reported severe exacerbations could make primary endpoint conclusions difficult” (see BioCentury, Oct. 24, 2016 ). Synairgen...
...16, 2014 ). Synairgen plc (LSE:SNG), Southampton, U.K. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Interferon beta (IFNB)...
...Indication: Treat respiratory virus-induced exacerbations of asthma Endpoint: NA Status: Development discontinued Milestone: NA Chris Lieu AZD9412 SNG001 AstraZeneca plc Synairgen...

...respiratory virus-induced exacerbations of asthma did not meet AstraZeneca's predefined progression criteria. In October 2016, Synairgen...
...could make primary endpoint conclusions difficult" (see BioCentury Extra, Oct. 12, 2016) . On Thursday, Synairgen...
...IP-10) and improved lung function as measured by morning peak expiratory flow (p=0.01) vs. placebo. Synairgen...

...issues a complete response letter for Qapzola apaziquone to treat non-muscle invasive bladder cancer (NMIBC) Synairgen...